急诊科阿片类使用障碍用药评估:2020年全国医院门诊医疗调查横断面分析
该研究利用2020年全国医院门诊医疗调查(NHAMCS)数据,纳入18-64岁因阿片类过量或阿片类使用障碍(OUD)就诊的急诊患者,估计阿片类使用障碍药物(MOUD)、可乐定或纳洛酮的使用比例,并以未校正比值比(OR)分析患者人口学、地区、共病及接诊人员特征与接受MOUD的关联。加权后因OUD或过量从急诊出院者共469,434例,其中54,123例(11.5%,95%CI 0-128,977)接受了至少一种MOUD;纳洛酮、可乐定和丁丙诺啡是最常使用的药物。西班牙裔种族(OR 17.9,95%CI 1.33-241.90)和西部地区的患者接受MOUD的比值升高,乘救护车到达者接受MOUD的比值降低(OR 0.01,95%CI 0.001-0.19),由高级执业提供者(APP)或医师助理接诊与接受MOUD相关(OR 16.68,95%CI 1.41-152.33;OR 13.84,95%CI 3.58-53.51)。作者认为MOUD及其他阿片类过量用药在急诊环境中使用不足,需进一步研究上述差异的根本原因。
要点
- 2020年因OUD或过量从急诊出院者加权共469,434例,仅54,123例(11.5%,95%CI 0-128,977)接受了至少一种MOUD。
- 纳洛酮、可乐定和丁丙诺啡是因OUD或过量最常给予和/或处方的药物。
- 西班牙裔种族(OR 17.9,95%CI 1.33-241.90)和西部地区(OR 43.77,95%CI 2.97-645.27)与接受MOUD的比值升高相关。
- 乘救护车到达与接受MOUD的比值降低相关(OR 0.01,95%CI 0.001-0.19)。
- 由APP接诊(OR 16.68,95%CI 1.41-152.33)或医师助理接诊(OR 13.84,95%CI 3.58-53.51)与接受MOUD相关。
适用人群与场景
- 2020年在美国急诊科就诊、年龄18-64岁、因阿片类过量或OUD就诊并从急诊出院(discharged from EDs)的患者。
研究设计与关键结果
- 研究类型:基于全国医院门诊医疗调查(NHAMCS)的横断面研究;数据由美国人口普查局调查人员从全国代表性急诊样本中收集。
- 加权后因OUD或过量从急诊出院者共469,434例;纳洛酮、可乐定和丁丙诺啡是最常给予和/或处方的药物。
- 54,123例(11.5%,95%CI 0-128,977)因OUD或过量从急诊出院者接受了至少一种MOUD。
- 西班牙裔种族与接受MOUD的比值升高相关(OR 17.9,95%CI 1.33-241.90);西部地区与接受MOUD的比值升高相关(OR 43.77,95%CI 2.97-645.27)。
- 乘救护车到达与接受MOUD的比值降低相关(OR 0.01,95%CI 0.001-0.19)。
- 由APP接诊(OR 16.68,95%CI 1.41-152.33)或医师助理接诊(OR 13.84,95%CI 3.58-53.51)与接受MOUD相关。
证据类型、等级与局限
- 证据类型:基于NHAMCS的横断面研究;关联以未校正OR及95%CI报告。
- 局限:作者指出MOUD及其他阿片类过量用药在急诊环境中使用不足,该发现尤其在种族、地理区域、来院方式和由APP接诊者中突出,强调需进一步研究这些差异的根本原因;作者认为本研究为MOUD使用模式提供了基础性认识,可指导未来研究。
对床旁实践的改变
- 作者认为MOUD及其他阿片类过量用药在急诊环境中使用不足;研究结果提示需进一步研究种族、地理区域、来院方式和由APP接诊者中用药差异的根本原因。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Opioid use disorder (OUD) is a significant health issue impacting millions in the United States (US). Medications used for OUD (MOUD) (e.g., buprenorphine, methadone, naltrexone) and medications for overdose and symptom management (e.g., naloxone, clonidine) have been shown to be safe and effective tools in clinical management. MOUD therapy in Emergency Departments (EDs) improves patient outcomes and enhances engagement with formal addiction treatment; however, provider factors and institutional barriers have created hurdles to ED-based MOUD treatment and heterogeneity in ED based OUD care. We used a nationally representative dataset, the National Hospital Ambulatory Medical Care Survey (NHAMCS) to characterize MOUD prescribing practices across patient demographics, geographic regions, payers, providers, and comorbidities in EDs.
METHODS: NHAMCS is a survey conducted by the US Census Bureau assessing utilization of ambulatory healthcare services nationally. Survey staff compile encounter records from a nationally representative sample of EDs. We conducted a cross-sectional study using this data to assess visits in 2020 among patients aged 18-64 presenting with an opioid overdose or OUD. We estimated the proportion of patients who had any MOUD, clonidine, or naloxone treatment and 95% confidence intervals (CI). We modeled the association between patient demographic, location, comorbidities, and provider characteristics with receipt of MOUD treatment as unadjusted odds ratios (OR) and 95% CI.
RESULTS: There was a weighted frequency of 469,434 patients who were discharged from EDs after being seen for OUD or overdose. Naloxone, clonidine, and buprenorphine were the most frequent treatments administered and/or prescribed for OUDs or overdose. Overall, 54,123 (11.5%, 95%CI 0-128,977) patients who were discharged from the ED for OUDs or overdose received at least one type of MOUD. Hispanic race, (OR 17.9, 95%CI 1.33-241.90) and Western region (OR43.77, 95%CI 2.97-645.27) were associated with increased odds of receiving MOUDs, while arrival by ambulance was associated with decreased odds of receiving MOUDs (OR0.01, 95%CI 0.001-0.19). Being seen by an APP or physician assistant was associated with MOUD treatment (OR 16.68, 95%CI: 1.41-152.33; OR: 13.84, 95%CI: 3.58-53.51, respectively).
CONCLUSION: Our study findings suggest that MOUD and other medications for opioid overdose are infrequently used in the ED setting. This finding was especially notable in race, geographic region, mode of arrival, and those seen by APP, underscoring the need for further study into the root causes of these disparities. Our study provides a foundational understanding of MOUD patterns, guiding future research as the landscape of OUD treatment continues to shift.
参考来源
- Lee S, Sun L, Vakkalanka JP, et al. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey. Am J Emerg Med. 2024. PMID: 38795424. doi:10.1016/j.ajem.2024.05.015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。